## HOUSE OF REPRESENTATIVES - FLOOR VERSION

STATE OF OKLAHOMA

1st Session of the 57th Legislature (2019)

By: Sims and McEntire

COMMITTEE SUBSTITUTE

FOR

5 HOUSE BILL NO. 1335

6

1

2

3

4

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

COMMITTEE SUBSTITUTE

An Act relating to insurance; creating the Protected Cell Companies Act; declaring purpose; providing definitions; providing for establishment of protective cell; requiring plan of operation; requiring approval of the Insurance Commissioner; providing for attributions of assets and liabilities; providing for legal status of protected cell; permitting right to contract; directing protected cell company to establish administrative and accounting procedures; prohibiting certain liabilities for protected cell assets; providing for valuation of assets; authorizing a protected cell company to engage in insurance securitization; requiring certain provisions be included in contracts or other documentation effecting the transaction; providing for close-out of protected cell account at the cessation of business; prohibiting issuance of certain contracts directly to policyholders or reinsureds; precluding availability of assets to certain creditors; precluding availability of assets to certain persons; providing for obligations relating solely to the general account; providing exception; providing for applicability and procedures during administrative supervision; providing for orders of rehabilitation or conservation; providing for challenge of an order of rehabilitation, conservation or liquidation; requiring permission of the Insurance Commissioner for voluntary winding up of a protected cell company; providing for payment from assets during rehabilitation, conservation or liquidation; providing for fines and penalties;

1 providing exceptions for certain persons; authorizing the Insurance Commissioner to promulgate rules; 2 providing for codification; and providing an effective date. 3 4 5 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 6 SECTION 1. NEW LAW A new section of law to be codified 7 in the Oklahoma Statutes as Section 1691 of Title 36, unless there is created a duplication in numbering, reads as follows: 8 9 This act shall be known and may be cited as the "Protected Cell 10 Companies Act". 11 SECTION 2. NEW LAW A new section of law to be codified 12 in the Oklahoma Statutes as Section 1692 of Title 36, unless there 13 is created a duplication in numbering, reads as follows: 14 The Protected Cell Companies Act is adopted to provide a basis 15 for the creation of protected cells by a domestic insurer as a means 16 of accessing alternative sources of capital and achieving the 17 benefits of insurance securitization or effectuating insurance 18 business transfers in accordance with the Insurance Business 19 Transfer Act. Investors in fully funded insurance securitization 20 transactions provide funds that are available to pay the insurer's 21 insurance obligations or to repay investors or both. The creation 22 of protected cells is intended to be a means to achieve more 23 efficiencies in conducting insurance securitizations or insurance

business transfers.

SECTION 3. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1693 of Title 36, unless there is created a duplication in numbering, reads as follows:

As used in the Protected Cell Companies Act:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- 1. "Commissioner" means the Oklahoma Insurance Commissioner;
- 2. "Domestic insurer" means an insurance or reinsurance company domiciled in the State of Oklahoma or a captive insurance or reinsurance company domiciled in the State of Oklahoma;
- "Fair value" of an asset or liability means the amount at which that asset or liability could be bought, incurred, sold or settled in a current transaction between willing parties other than in a forced or liquidation sale. Quoted market prices in active markets are the best evidence of fair value and shall be used as the basis for the measurement, if available. If a quoted market price is available, the fair value is the product of the number of trading units times market price. If quoted market prices are not available, the estimate of fair value shall be based on the best information available. The estimate of fair value shall consider prices for similar assets and liabilities and the results of valuation techniques to the extent available in the circumstances. Examples of valuation techniques include the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved, option pricing models, matrix pricing, option-adjusted spread models and fundamental analysis.

Valuation techniques for measuring financial assets and liabilities and servicing assets and liabilities shall be consistent with the objective of measuring fair value. Those techniques shall incorporate assumptions that market participants would use in their estimates of values, future revenues and future expenses, including assumptions about interest rates, default, prepayment and volatility. When measuring financial liabilities and servicing liabilities at fair value by discounting estimated future cash flows, the objective is to use discount rates at which those liabilities could be settled in an arm's-length transaction. Estimates of expected future cash flows, if used to estimate fair value, shall be the best estimate based on reasonable and supportable assumptions and projections. All available evidence shall be considered in developing estimates of expected future cash The weight given to the evidence shall be commensurate with the extent to which the evidence can be verified objectively. range is estimated for the amount or timing of possible cash flows, the likelihood of possible outcomes shall be considered in determining the best estimate of future cash flows;

4. "Fully funded" means that, with respect to any exposure attributed to a protected cell, the fair value of the protected cell assets, on the date on which the insurance securitization is effected, equals or exceeds the maximum possible exposure attributable to the protected cell with respect to those exposures;

1

2

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- 5. "General account" means the assets and liabilities of a protected cell company other than protected cell assets and protected cell liabilities;
- 6. "Indemnity trigger" means a transaction term by which relief of the issuer's obligation to repay investors is triggered by its incurring a specified level of losses under its insurance or reinsurance contracts;
- 7. "Nonindemnity trigger" means a transaction term by which relief of the issuer's obligation to repay investors is triggered solely by some event or condition other than the individual protected cell company incurring a specified level of losses under its insurance or reinsurance contracts;
- 8. "Protected cell" means an identified pool of assets and liabilities of a protected cell company segregated and insulated by means of this act from the remainder of the protected cell company's assets and liabilities;
- 9. "Protected cell account" means a specifically identified bank or custodial account established by a protected cell company for the purpose of segregating the protected cell assets of one protected cell from the protected cell assets of other protected cells and from the assets of the protected cell company's general account;

1.3

- 10. "Protected cell assets" means all assets, contract rights and general intangibles identified with and attributable to a specific protected cell of a protected cell company;
- 11. "Protected cell company" means a domestic insurer that has one or more protected cells;
- 12. "Protected cell company insurance securitization" means the issuance of debt instruments, the proceeds from which support the exposures attributed to the protected cell, by a protected cell company, where repayment of principal and/or interest to investors pursuant to the transaction terms is contingent upon the occurrence or nonoccurrence of an event with respect to which the protected cell company is exposed to loss under insurance or reinsurance contracts it has issued;
- 13. "Protected cell liabilities" means all liabilities and other obligations identified with and attributable to a specific protected cell of a protected cell company; and
- 14. "Receiver" means the Commissioner, where the Commissioner is acting as a rehabilitator, liquidator or administrative supervisor of a company, or any person appointed to carry out an order of rehabilitation or liquidation of a company.
- SECTION 4. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1694 of Title 36, unless there is created a duplication in numbering, reads as follows:

1.3

2.1

A. A protected cell company may establish one or more protected
cells, with the prior written approval of the Insurance Commissioner
of a plan of operation or amendments to a plan of operation
submitted by the protected cell company with respect to each
protected cell. Upon the written approval of the Commissioner of
the plan of operation or amendments to a plan of operation, which
shall include, but not be limited to, the specific business
objectives and investment guidelines of the protected cell, the
protected cell company may, in accordance with the approved plan of
operations, attribute to the protected cell amounts both reflective
of insurance obligations with respect to its insurance business and
obligations relating to the insurance securitization and assets to
fund the obligations. Each protected cell of a protected cell
company shall have its own distinct name or designation, which shall
include the words "protected cell". The protected cell company
shall transfer all assets attributable to each protected cell to one
or more separately established and identified protected cell
accounts bearing the name or designation of that protected cell.
Protected cell assets shall be held in the protected cell accounts
for the purpose of satisfying the obligations of that protected
cell.

B. All attributions of assets and liabilities between a protected cell and the general account shall be in accordance with the plan of operation approved by the Commissioner or shall be

otherwise approved by the Commissioner. Unless otherwise approved by the Commissioner, no other attribution of assets or liabilities shall be made by a protected cell company between the protected cell company's general account and one or more of its protected cells. Any attribution of assets and liabilities between the general account and a protected cell, or from investors in the form of principal on a debt instrument issued by a protected cell company in connection with a protected cell company securitization, shall be in cash or readily marketable securities with established market values unless otherwise approved in advance in writing by the Commissioner.

- C. The creation of a protected cell does not create, in respect of that protected cell, a legal person separate from the protected cell company. Amounts attributed to a protected cell under this act, including assets transferred to a protected cell account, are owned by the protected cell company and the protected cell company may not be, nor hold itself out to be, a trustee with respect to those protected cell assets of that protected cell account.

  Notwithstanding the foregoing, the protected cell company may allow for a security interest to attach to protected cell assets or a protected cell account when in favor of a creditor of the protected cell and otherwise allowed under applicable law.
- D. Nothing in the Protected Cell Companies Act shall be construed to prohibit the protected cell company from contracting with or arranging for an investment advisor, commodity trading

advisor or other third party to manage the protected cell assets of a protected cell, provided that all remuneration, expenses and other compensation of the third-party advisor or manager are payable from the protected cell assets of that protected cell and not from the protected cell assets of other protected cells or the assets of the protected cell company's general account. The contract shall clearly reference the protected cell or cells for which the contract has been arranged and shall contain a nonrecourse provision in favor of the company that prohibits the contracting party from seeking recourse against, or attaching, the assets of the general account, or the assets of another protected cell, to satisfy the obligations of any one or more protected cells which are the subject of the contract.

- E. A protected cell company shall establish any administrative and accounting procedures that are necessary to properly identify the one or more protected cells of the protected cell company and the protected cell assets and protected cell liabilities attributable to the protected cells. It shall be the duty of the directors of a protected cell company to:
- 1. Keep protected cell assets and protected cell liabilities separate and separately identifiable from the assets and liabilities of the protected cell company's general account; and
- 2. Keep protected cell assets and protected cell liabilities attributable to one protected cell separated and separately

1.3

identifiable from protected cell assets and protected cell liabilities attributable to other protected cells.

Notwithstanding other provisions of this section, and subject to the provisions of Section 10 of this act, if this section is violated, the remedy of tracing shall be applicable to protected cell assets when commingled with protected cell assets of other protected cells or the assets of the protected cell company's general account. The remedy of tracing shall not be construed as an exclusive remedy.

- F. Unless otherwise approved by the Commissioner, the protected cell company shall, when establishing a protected cell, attribute the protected cell assets a value at least equal to the reserves and other insurance liabilities attributed to that protected cell.
- SECTION 5. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1695 of Title 36, unless there is created a duplication in numbering, reads as follows:
- A. The protected cell assets of any protected cell shall not be charged with liabilities arising out of any other business the protected cell company may conduct. All contracts or other documentation reflecting protected cell liabilities shall clearly indicate that only the protected cell assets are available for the satisfaction of those protected cell liabilities.

1.3

- B. Unless otherwise approved by the Insurance Commissioner, assets attributed to a protected cell shall be valued at their fair value on the date of valuation.
- C. The income, gains and losses, realized or unrealized, from protected cell assets and protected cell liabilities shall be credited to or charged against the protected cell without regard to other income, gains or losses of the protected cell company, including income, gains or losses of other protected cells. Amounts attributed to any protected cell and accumulations on the attributed amounts may be invested and reinvested without regard to any requirements or limitations imposed on investments of insurance companies domiciled in this state and the investments in any protected cell or cells may not be taken into account in applying the investment limitations otherwise applicable to the investments of the protected cell company, subject to any restrictions that may be imposed by the Commissioner in accordance with Section 12 of this act.
- D. As permitted by the Commissioner, a protected cell company may, in respect of any of its protected cells, engage in fully funded indemnity triggered and/or fully funded nonindemnity triggered insurance securitization to support in full the protected cell exposures attributable to that protected cell. A protected cell company insurance securitization that is nonindemnity triggered shall qualify as an insurance securitization under the terms of this

section only after the Commissioner, in accordance with the authority granted under Section 12 of this act, adopts regulations addressing the methods of funding of the portion of the risk that is not indemnity-based, accounting, disclosure, risk-based capital treatment, and assessing risks associated with those securitizations. A protected cell company insurance securitization that is not fully funded, whether indemnity triggered or nonindemnity triggered, is prohibited. Protected cell assets may be used to pay interest or other consideration on any outstanding debt or other obligation attributable to that protected cell, and nothing in this section shall be construed or interpreted as preventing a protected cell company from entering into a swap agreement or other transaction for the account of the protected cell that has the effect of guaranteeing that interest or other consideration.

E. In all protected cell company insurance securitizations, the contracts or other documentation effecting the transaction shall contain provisions identifying the protected cell to which the transaction will be attributed. In addition, the contracts or other documentation shall clearly disclose that the assets of that protected cell, and only those assets, are available to pay the obligations of that protected cell. Notwithstanding the foregoing, and subject to the provisions of this title and any other applicable law or rules, the failure to include that language in the contracts or other documentation shall not be used as the sole basis by

creditors, reinsurers or other claimants to circumvent the provisions of this section.

- F. At the cessation of business of a protected cell, and in absence of any placement under administrative supervision or order of conservation, rehabilitation or liquidation attributable to that protected cell or the protected cell company, the protected cell company shall voluntarily close out the protected cell account in accordance with a plan approved by the Commissioner.
- G. A protected cell company shall only be authorized to attribute to a protected cell account the insurance obligations relating to the protected cell company's general account. Under no circumstances shall a protected cell be authorized to issue insurance or reinsurance contracts directly to policyholders or reinsureds or have any obligation to the policyholders or reinsureds of the protected cell company's general account.
- SECTION 6. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1696 of Title 36, unless there is created a duplication in numbering, reads as follows:
- A. 1. Protected cell assets shall only be available to the creditors of the protected cell company that are creditors in respect to that protected cell and shall be entitled, in conformity with the provisions of the Protected Cell Companies Act, to have recourse to the protected cell assets attributable to that protected cell, and shall be absolutely protected from the creditors of the

- protected cell company that are not creditors in respect of that

  protected cell and, who accordingly, shall not be entitled to have

  recourse to the protected cell assets attributable to that protected

  cell. Creditors with respect to a protected cell shall not be

  entitled to have recourse against the protected cell assets of other

  protected cells or the assets of the protected cell company's

  general account.
  - 2. Protected cell assets shall only be available to creditors of a protected cell company after all protected cell liabilities have been extinguished or provided for in accordance with the plan of operation relating to that protected cell.
  - B. When an obligation of a protected cell company to a person arises from a transaction, or is imposed, in respect of a protected cell:
    - 1. That obligation of the protected cell company shall extend only to the protected cell assets attributable to that protected cell, and the person shall, with respect to that obligation, be entitled to have recourse only to the protected cell assets attributable to that protected cell; and
    - 2. That obligation of the company shall not extend to the protected cell assets of any other protected cell or the assets of the protected cell company's general account, and that person shall not, with respect to that obligation, be entitled to have recourse

- to the protected cell assets of any other protected cell or the assets of the protected cell company's general account.
- C. When an obligation of a protected cell company relates solely to the general account, the obligation of the protected cell company shall extend only to, and that creditor shall, with respect to that obligation, be entitled to have recourse only to, the assets of the protected cell company's general account.
- D. Other than with regard to the application of this section, the activities, assets and obligations relating to a protected cell are not subject to the provisions of Articles 20A and 20B of Title 36 of the Oklahoma Statutes and neither a protected cell nor a protected cell company shall be assessed by or be required to contribute to any guaranty fund or guaranty association in this state with respect to the activities, assets or obligations of a protected cell. Nothing in this section shall affect the activities or obligations of an insurer's general account.
- E. In no event shall the establishment of one or more protected cells alone constitute or be deemed to be a fraudulent conveyance, an intent by the protected cell company to defraud creditors, or the carrying out of business by the protected cell company for any other fraudulent purpose.
- SECTION 7. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1697 of Title 36, unless there is created a duplication in numbering, reads as follows:

- A. Notwithstanding any contrary provision in the Oklahoma
  Insurance Code, the rules promulgated under the Oklahoma Insurance
  Code or any other applicable law or rule, upon placement under
  administrative supervision or upon any order of conservation,
  rehabilitation or liquidation of a protected cell company, the
  receiver shall be bound to deal with the protected cell company's
  assets and liabilities, including protected cell assets and
  protected cell liabilities, in accordance with the requirements set
  forth in the Protected Cell Companies Act.
- B. With respect to amounts recoverable under a protected cell company insurance securitization, the amount recoverable by the receiver shall not be reduced or diminished as a result of the placement under administrative supervision or entry of an order of conservation, rehabilitation or liquidation with respect to the protected cell company or any of its protected cells, notwithstanding any provisions to the contrary in the contracts or other documentation governing the protected cell company insurance securitization.
- SECTION 8. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1698 of Title 36, unless there is created a duplication in numbering, reads as follows:
- A. If in relation to one or more protected cells of a protected cell company, the Insurance Commissioner is satisfied that the protected cell assets attributable to that protected cell are

insufficient to discharge the claims of creditors or other claimants with respect to that protected cell, the Commissioner may place under administrative supervision or apply for an order of conservation, rehabilitation or liquidation with respect to that protected cell. In carrying out the administrative supervision, conservation, rehabilitation or liquidation of a protected cell, the receiver shall follow generally the provisions of Articles 1, 6, 18 and 19 of Title 36 of the Oklahoma Statutes, as applicable, and any rules and regulations promulgated under those articles, except that at all times the receiver shall be bound to deal with the protected cell assets and protected cell liabilities in accordance with the requirements of the Protected Cell Companies Act.

- B. An order of rehabilitation or conservation shall not be requested or made with respect to any protected cell of a protected cell company if a receiver has been appointed to act in respect of a protected cell company and the Commissioner may still apply for an order of liquidation with respect to that protected cell. Any prior order of rehabilitation or conservation with respect to a protected cell shall cease to be of effect upon an order of rehabilitation with respect to the protected cell company, without prejudice to the prior acts of the receiver or its agents.
- C. An order of rehabilitation, conservation or liquidation shall not be requested or made with respect to any protected cell of a protected cell company if a liquidator has been appointed to act

1.3

- in respect of the protected cell company. Any prior order of
  rehabilitation, conservation or liquidation with respect to a
  protected cell shall cease to be of effect upon an order of
  liquidation with respect to the protected cell company, without
  prejudice to the prior acts of the receiver or its agent.
  - D. During any period of conservation or rehabilitation, or upon an order of liquidation, with respect to a protected cell, the directors of the protected cell company shall cease in respect of the business of, and the protected cell assets and protected cell liabilities attributable to, the protected cell which is the subject of the rehabilitation, conservation or liquidation.
  - E. In the event that a petition for an order of rehabilitation, conservation or liquidation of a protected cell is challenged, prior to the entry or denial of the order, the directors of the protected cell company shall cease in respect of the business of, and the protected cell assets and protected cell liabilities attributable to, the protected cell which is the subject of the petition and the Commissioner shall carry out the business of the protected cell until the order has been entered or denied. In the event the order is denied, the Commissioner shall immediately return possession and control of the protected cell to the directors of the protected cell company.
  - F. No resolution for the voluntary winding up of a protected cell company with any protected cell which has been placed under

administrative supervision or is the subject of an order of
rehabilitation, conservation or liquidation shall be effective
without permission of the Commissioner and, in the case of
rehabilitation, conservation or liquidation, the court supervising
the rehabilitation, conservation or liquidation.

- SECTION 9. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1699 of Title 36, unless there is created a duplication in numbering, reads as follows:
- A. With respect to orders of rehabilitation, conservation or liquidation directed at a protected cell company, the remuneration, expenses and other compensation of the receiver shall be payable from the assets of the company's general account, in accordance with the priority of distribution set forth in Section 1927.1 of Title 36 of the Oklahoma Statutes.
- B. With respect to orders of rehabilitation, conservation or liquidation directed at a protected cell company, the remuneration, expenses and other compensation of the receiver shall be payable from the protected cell assets attributable to that protected cell. In the case where more than one protected cell is the subject of the order, the receiver shall account for remuneration, expenses and other compensation separately for each protected cell in accordance with actual time and expenses attributable to the rehabilitation, conservation or liquidation of each respective protected cell.

C. With respect to orders of rehabilitation, conservation or liquidation directed at a protected cell company during a pending rehabilitation, conservation or liquidation of one or more protected cells, the remuneration, expenses and other compensation of the receiver of the protected cells shall be satisfied from the protected cell assets of the protected cell or cells in accordance with the provisions of subsection B of this section, and the remuneration, expenses and other compensation of the receiver of the protected cell company shall be satisfied from the assets of the company's general account.

SECTION 10. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1699.1 of Title 36, unless there is created a duplication in numbering, reads as follows:

Any person violating the provisions of the Protected Cell
Companies Act shall be subject to any and all enforcement procedures
either currently employed or subsequently promulgated by the
Insurance Commissioner including, but not limited to, the imposition
of fines, sanctions or civil penalties, or an order to cease and
desist from the establishment of additional protected cells. In no
event shall the Commissioner have the authority to cease the
business of an existing protected cell, except by placement under
administrative supervision or by order of rehabilitation,
conservation or liquidation in accordance with the provisions of
this act.

SECTION 11. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1699.2 of Title 36, unless there is created a duplication in numbering, reads as follows:

A protected cell company insurance securitization shall not be deemed to be an insurance or reinsurance contract. An investor in a protected cell company insurance securitization shall not, by sole means of this investment, be deemed to be transacting an insurance business in this state. The underwriters or selling agents and their partners, directors, officers, members, managers, employees, agents, representatives and advisors involved in a protected cell company insurance securitization shall not be deemed to be conducting an insurance or reinsurance agency, brokerage, intermediary, advisory or consulting business by virtue of their activities in connection with those businesses.

SECTION 12. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1699.3 of Title 36, unless there is created a duplication in numbering, reads as follows:

The Insurance Commissioner may promulgate reasonable rules as may be necessary to effectuate the purposes of the Protected Cell Companies Act.

SECTION 13. This act shall become effective November 1, 2019.

COMMITTEE REPORT BY: COMMITTEE ON INSURANCE, dated 02/27/2019 - DO PASS, As Amended and Coauthored.

2.1